Literature DB >> 3440246

Clinically useful doxorubicin analogues.

F Arcamone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3440246     DOI： 10.1016/0305-7372(87)90002-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

Review 1.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

2.  Interaction of Anthracycline 3'-azido-epirubicin with Calf Thymus DNA via Spectral and Molecular Modeling Techniques.

Authors:  Fengling Cui; Xiaoqing Niu; Luyao Li; Pengge Zhang; Guisheng Zhang
Journal:  J Fluoresc       Date:  2015-06-25       Impact factor: 2.217

Review 3.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

4.  The Mechanism of Dynamic Interaction between Doxorubicin and Calf Thymus DNA at the Single-Molecule Level Based on Confocal Raman Spectroscopy.

Authors:  Ruihong Zhang; Jie Zhu; Dan Sun; Jie Li; Lina Yao; Shuangshuang Meng; Yan Li; Yang Dang; Kaige Wang
Journal:  Micromachines (Basel)       Date:  2022-06-13       Impact factor: 3.523

5.  Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts.

Authors:  M V Pimm; M A Paul; Y Ogumuyiwa; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26.

Authors:  M Iigo; K Nishikata; Y Nakajima; A Hoshi
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.